Therapeutic Apheresis and Dialysis最新文献

{"title":"Effects of intradialytic exercise in combination with melatonin supplementation on functional capacity, postural balance, and quality of life in hemodialysis patients.","authors":"Houssem Marzougui,&nbsp;Rami Maaloul,&nbsp;Imen Ben Dhia,&nbsp;Salma Toumi,&nbsp;Khawla Kammoun,&nbsp;Mohamed Ben Hmida,&nbsp;Fatma Ayadi,&nbsp;Mouna Turki,&nbsp;Mohamed Habib Elleuch,&nbsp;Sameh Ghroubi,&nbsp;Omar Hammouda","doi":"10.1111/1744-9987.13964","DOIUrl":"https://doi.org/10.1111/1744-9987.13964","url":null,"abstract":"<p><strong>Introduction: </strong>We evaluated the effect of intradialytic concurrent (resistance-endurance) training combined with melatonin (MEL) supplementation on functional capacity, muscle strength, postural balance, and quality of life (QoL) in hemodialysis (HD) patients.</p><p><strong>Methods: </strong>Thirty-three HD patients were randomized into three groups: Exercise (EX)-MEL (n = 11); EX-Placebo (PLA) (n = 11) and Control (C)-PLA (n = 11). Participants included in the EX-MEL and EX-PLA groups were submitted to concurrent training for 12 weeks.</p><p><strong>Results: </strong>EX-MEL and EX-PLA improved functional capacity, muscle strength, QoL, and postural balance parameters in eyes open and eyes closed conditions. Parameters of postural balance in the dual task condition were improved only in EX-MEL. EX-MEL induced better results in some domains of QoL compared with EX-PLA.</p><p><strong>Conclusion: </strong>Intradialytic concurrent training induced beneficial effects on physical function, muscle strength, postural balance, and QoL in HD patients. MEL supplementation combined with intradialytic exercise lead to better improvements in postural balance and QoL.</p>","PeriodicalId":23021,"journal":{"name":"Therapeutic Apheresis and Dialysis","volume":"27 4","pages":"669-681"},"PeriodicalIF":1.9,"publicationDate":"2023-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9732260","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"COVID-19 vaccine uptake rates, perceptions, and attitudes among dialysis patients: Experience across a national sample.","authors":"Balzan Deborah,&nbsp;Stefanie Marie Agius,&nbsp;Farrugia Emanuel,&nbsp;Buttigieg Jesmar","doi":"10.1111/1744-9987.13983","DOIUrl":"https://doi.org/10.1111/1744-9987.13983","url":null,"abstract":"<p><strong>Introduction: </strong>Dialysis patients are at increased risk of severe COVID-19 infection making vaccination a priority. We explored COVID-19 vaccine uptake and perceptions in our dialysis population, associated COVID-19 infection, and hospitalization rates.</p><p><strong>Methods: </strong>This is a single-center retrospective study using telephone questionnaires and hospital records to investigate COVID-19 vaccine uptake and attitudes behind vaccination status.</p><p><strong>Results: </strong>A total of 230 patients were interviewed. Vaccine uptake was 97.8% (two doses) and 86.6% (booster dose), with 79.5% vaccinated at Renal Unit. Most (58.5%) cited healthcare worker advice as a contributing factor and 54% sought protection through vaccination. COVID-19 hospitalization was higher in unvaccinated and patients vaccinated with one dose, compared to two doses (63.2% vs. 20%, p = 0.05) and booster dose (63.2% vs. 22.2%, p = 0.02).</p><p><strong>Conclusion: </strong>Our dialysis population recognized the importance of COVID-19 vaccination. Intensive patient education and easy access to the COVID-19 vaccine may have facilitated vaccine uptake in these patients.</p>","PeriodicalId":23021,"journal":{"name":"Therapeutic Apheresis and Dialysis","volume":"27 4","pages":"726-734"},"PeriodicalIF":1.9,"publicationDate":"2023-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9741219","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"IN.PACT AV access randomized trial: Japan cohort outcomes through 12 months.","authors":"Hiroaki Haruguchi,&nbsp;Kotaro Suemitsu,&nbsp;Naoko Isogai,&nbsp;Masaaki Murakami,&nbsp;Masahiko Fujihara,&nbsp;Kazuhiro Iwadoh,&nbsp;Jeremiah Menk,&nbsp;Hiroko Ookubo,&nbsp;Tomonari Ogawa,&nbsp;Levester Kirksey,&nbsp;Sanjay Misra,&nbsp;Angelo Santos,&nbsp;Chad Laurich,&nbsp;Omran Abul-Khoudoud,&nbsp;Adie Friedman,&nbsp;Vincent Gallo,&nbsp;Ahmed Kamel Abdel Aal,&nbsp;Mel Sharafuddin,&nbsp;Sreekumar Madassery,&nbsp;David Dexter,&nbsp;Charles Joels,&nbsp;Syed Hussain,&nbsp;Sandeep Bagla,&nbsp;Jeffrey Hull,&nbsp;John Ross,&nbsp;Jeffrey Hoggard,&nbsp;Bret Wiechmann,&nbsp;Naveen Atray,&nbsp;Randy Cooper,&nbsp;Neghae Mawla,&nbsp;Fernando Kafie,&nbsp;Kotaro Suemitsu,&nbsp;Naoko Isogai,&nbsp;Masahiko Fujihara,&nbsp;Masaaki Murakami,&nbsp;Shohei Fuchinoue,&nbsp;Kazuhiro Iwadoh,&nbsp;Tomonari Ogawa,&nbsp;Andrew Holden,&nbsp;Kesaka Wickremesekera","doi":"10.1111/1744-9987.13966","DOIUrl":"https://doi.org/10.1111/1744-9987.13966","url":null,"abstract":"<p><strong>Purpose: </strong>There is a lack of adjudicated and prospectively randomized published outcomes on the use of drug-coated balloons (DCB) to treat dysfunctional arteriovenous fistula in Asian patients. This post hoc subgroup analysis of 112 Japanese participants from the global IN.PACT AV Access trial reports outcomes through 12 months.</p><p><strong>Materials and methods: </strong>Participants were treated with DCB (n = 58) or standard non-coated percutaneous transluminal angioplasty (PTA) balloons (n = 54). Outcomes included target lesion primary patency (TLPP), access circuit primary patency, and safety.</p><p><strong>Results: </strong>Through 6 months, TLPP was 86.0% (49/57) in the DCB group and 49.1% (26/53) in the PTA group (p < 0.001). Through 12 months, TLPP was 67.3% (37/55) in the DCB group and 43.4% (23/53) in the PTA group (p = 0.013).</p><p><strong>Conclusion: </strong>In this post hoc analysis of Japanese participants from the IN.PACT AV Access trial, participants treated with DCB had higher TLPP through 6 and 12 months compared with PTA.</p>","PeriodicalId":23021,"journal":{"name":"Therapeutic Apheresis and Dialysis","volume":"27 4","pages":"682-693"},"PeriodicalIF":1.9,"publicationDate":"2023-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9739291","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Comparison the effect of valerian and gabapentin on RLS and sleep quality in hemodialysis patients: A randomized clinical trial.","authors":"Iman Hajizadeh,&nbsp;Mahdieh Jamshidi,&nbsp;Majid Kazemi,&nbsp;Hossein Kargar,&nbsp;Tabandeh Sadeghi","doi":"10.1111/1744-9987.13987","DOIUrl":"https://doi.org/10.1111/1744-9987.13987","url":null,"abstract":"<p><strong>Introduction: </strong>This study aimed to compare the effect of valerian and gabapentin on restless legs syndrome (RLS) and sleep quality in HD patients.</p><p><strong>Methods: </strong>In this cross over clinical trial study, 40 HD patients allocated into a valerian and gabapentin group. In the first phase of the study, Group A received valerian and Group B received gabapentin 1 h before bedtime for 1 month. In the second phase, the two groups' treatment regimen was swapped. After a 1-month washout period, the same process was repeated on the crossover groups.</p><p><strong>Results: </strong>After the first phase, the mean score of RLS was lower in the gabapentin group. But there was no statistically significant difference between the two groups in terms of sleep quality score before and after the first and second interventions.</p><p><strong>Conclusion: </strong>Gabapentin is more effective than valerian in improving RLS, but both are equally effective in improving sleep quality.</p>","PeriodicalId":23021,"journal":{"name":"Therapeutic Apheresis and Dialysis","volume":"27 4","pages":"621-628"},"PeriodicalIF":1.9,"publicationDate":"2023-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9797834","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Survey on patient satisfaction with a one-hour discussion on the choice of dialysis modality at the outpatient clinic.","authors":"Tsutomu Sakurada,&nbsp;Kaori Kohatsu,&nbsp;Shigeki Kojima","doi":"10.1111/1744-9987.13985","DOIUrl":"https://doi.org/10.1111/1744-9987.13985","url":null,"abstract":"Dear Editor, It is widely known that shared decision-making (SDM) is a superior approach when choosing the dialysis modality in patients with end-stage kidney disease (ESKD). However, its impact on patient satisfaction has not been well investigated. We conducted this survey to clarify patient satisfaction with a 1-h discussion on the choice of dialysis modality at the outpatient clinic. This anonymous survey included ESKD patients who visited our outpatient clinic between February 10, 2020 and March 31, 2022. Details of the outpatient clinic have been described in a previous report [1]. Return of a completed questionnaire by the patient was considered as consent for study participation. Of the 74 patients who returned the questionnaire, 65 patients who fully completed it were included in the analysis. This survey was based on the Ministry of Health, Labor and Welfare's survey, evaluated on a 5-point scale (very satisfied, satisfied, neutral, somewhat dissatisfied, and very dissatisfied). Patient background items, such as age group, sex, underlying disease causing ESKD, history of nephrology visits, employment status, and cohabitation status. Subjective understanding of the clinical implications of hemodialysis (HD) and peritoneal dialysis (PD) before and after outpatient visits (rated on a 10-point scale) was also included. Forty-six patients were over 70 years old, 49 were male, and diabetic nephropathy was the cause of ESKD in 17 patients. Forty-eight patients had a history of nephrology consultations for more than 1 year, 19 were employed, and 58 lived with someone. Subjective comprehension of dialysis modality significantly increased after outpatient visits compared to before the visits (HD: 7.7 ± 1.8 vs. 4.9 ± 2.4 points, PD: 7.0 ± 2.3 vs. 3.7 ± 2.6 points, p &lt; 0.01, respectively). Eighty-three percent of the patients responded that they were satisfied or very satisfied (Figure 1). Ordinal logistic regression analysis of factors associated with patient satisfaction revealed that patients with less than 1 year of nephrology outpatient visits had higher patient satisfaction than those with longer histories of consultations (odds ratio = 3.672 [95% confidence interval: 1.143, 11.792, p = 0.029]). A survey has been performed to assess treatment satisfaction for dialysis patients [2]. However, few studies have been performed to assess patient satisfaction with SDM for non-dialysis patients. The present study showed that patient satisfaction was not associated with improved subjective comprehension and was higher in patients with a short history of nephrology visits. It has been reported that patient satisfaction is associated with attendance at dialysis sessions [3]. Furthermore, surveying patient satisfaction provides feedback from ESKD patients and may lead to improved quality of care. However, the outcomes cannot be assessed due to this anonymous study. Late referral patients often do not have sufficient acceptance of ESKD, and we speculated ","PeriodicalId":23021,"journal":{"name":"Therapeutic Apheresis and Dialysis","volume":"27 4","pages":"813-814"},"PeriodicalIF":1.9,"publicationDate":"2023-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9814218","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Immunoadsorption to treat patients with severe post-COVID syndrome.","authors":"Benjamin Giszas,&nbsp;Philipp A Reuken,&nbsp;Katrin Katzer,&nbsp;Michael Kiehntopf,&nbsp;Diana Schmerler,&nbsp;Silke Rummler,&nbsp;Andreas Stallmach,&nbsp;Anne Klink","doi":"10.1111/1744-9987.13974","DOIUrl":"https://doi.org/10.1111/1744-9987.13974","url":null,"abstract":"<p><strong>Introduction: </strong>Following SARS-CoV-2-infection up to 21% of patients will develop post-COVID-syndrome. Autoantibodies (AAbs) targeting neuronal-ß-adrenergic and muscarinic receptors may provide crucial contributions to the pathophysiology of this condition. Immunoadsorption (IA) has been identified as an effective means of removing AAbs and has resulted in clinical improvements of other autoantibody-associated diseases.</p><p><strong>Methods: </strong>We determined AAb-levels (anti-ß1/ß2 and anti-M3/M4 receptor) in 178 patients diagnosed with post-COVID-syndrome and described the clinical courses of two patients with elevated AAb-levels that underwent IA-treatment.</p><p><strong>Results: </strong>AAbs were detected in 57% (101/178) of patients diagnosed with post-COVID-syndrome. Substantial reductions in AAb-levels and clinical remission were achieved in one of two patients who was treated with IA. However, this patient relapsed within 6 weeks with a concomitant increase in AAb-levels.</p><p><strong>Conclusion: </strong>Collectively, AAbs may play a pathophysiologic role in post-COVID and their removal provide transient benefits in some patients. However, these findings should be further investigated in randomized-controlled-trials.</p>","PeriodicalId":23021,"journal":{"name":"Therapeutic Apheresis and Dialysis","volume":"27 4","pages":"790-801"},"PeriodicalIF":1.9,"publicationDate":"2023-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9968491","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Impact of COVID-19 on maintenance peritoneal dialysis patients and providers: A review.","authors":"David F Painter,&nbsp;Braden Vogt,&nbsp;Anagha Lokhande,&nbsp;Rodrigo Saad Berreta,&nbsp;Ankur D Shah","doi":"10.1111/1744-9987.13993","DOIUrl":"https://doi.org/10.1111/1744-9987.13993","url":null,"abstract":"<p><p>The COVID-19 pandemic exerted complex pressures on the nephrology community. Despite multiple prior reviews on acute peritoneal dialysis during the pandemic, the effects of COVID-19 on maintenance peritoneal dialysis patients remain underexamined. This review synthesizes and reports findings from 29 total cases of chronic peritoneal dialysis patients with COVID-19, encompassing 3 case reports, 13 case series, and 13 cohort studies. When available, data for patients with COVID-19 on maintenance hemodialysis are also discussed. Finally, we present a chronological timeline of evidence regarding the presence of SARS-CoV-2 in spent peritoneal dialysate and explore trends in telehealth as they relate to peritoneal dialysis patients during the pandemic. We conclude that the COVID-19 pandemic has underscored the efficacy, flexibility, and utility of peritoneal dialysis.</p>","PeriodicalId":23021,"journal":{"name":"Therapeutic Apheresis and Dialysis","volume":"27 4","pages":"607-620"},"PeriodicalIF":1.9,"publicationDate":"2023-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10118625","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Correction to \"Prostacyclin analog beraprost sodium efficacy in primary glomerular disease or nephrosclerosis: Analysis of the Japanese subgroup in CASSIOPEIR study\".","authors":"","doi":"10.1111/1744-9987.13986","DOIUrl":"https://doi.org/10.1111/1744-9987.13986","url":null,"abstract":"","PeriodicalId":23021,"journal":{"name":"Therapeutic Apheresis and Dialysis","volume":"27 4","pages":"825"},"PeriodicalIF":1.9,"publicationDate":"2023-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10479993/pdf/TAP-27-825.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10175525","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"A novel device and system concept for therapeutic plasma exchange in rats.","authors":"Mitică Ciorpac,&nbsp;Cezar-Cătălin Caratașu,&nbsp;Andrei Szilagyi,&nbsp;Cosmin-Teodor Mihai,&nbsp;Ionut Nistor,&nbsp;Radu Iliescu,&nbsp;Bogdan Ionel Tamba","doi":"10.1111/1744-9987.13989","DOIUrl":"https://doi.org/10.1111/1744-9987.13989","url":null,"abstract":"<p><strong>Introduction: </strong>Therapeutic plasma exchange (TPE) has been developed more than 100 years ago in an animal model and adapted to humans 30 years later. Since then, the TPE research on animal models is lacking, mainly due to difficulties raised by the scaling of the plasmapheresis unit so that the animal's cardiovascular parameters are not considerably affected.</p><p><strong>Methods: </strong>The system concept of a novel TPE device with continuous hemodynamic monitoring in small rodent models has been used.</p><p><strong>Results: </strong>A continuum TPE unit for rats has been developed, able to produce up to 95% plasma exchange rate without any TPE-related hemodynamic impairment, monitored up to 35 days after the procedure.</p><p><strong>Conclusion: </strong>The TPE unit for rats was able to produce 95% plasma exchange rate in non-anesthetized animals, enabling a full translation of the human TPE into an animal model. The newly developed plasmapheresis unit enable a wide range of more accurate preclinical evaluation, with cardiac parameters monitoring, using small rodents in awaken state.</p>","PeriodicalId":23021,"journal":{"name":"Therapeutic Apheresis and Dialysis","volume":"27 4","pages":"771-779"},"PeriodicalIF":1.9,"publicationDate":"2023-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9742529","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Successful pregnancy in a hemodialysis patient with primary hyperoxaluria type 1.","authors":"Franka Zuban,&nbsp;Ranko Ladavac,&nbsp;Nikolina Basic-Jukic","doi":"10.1111/1744-9987.13995","DOIUrl":"https://doi.org/10.1111/1744-9987.13995","url":null,"abstract":"Dear Editor Better dialysis technique has contributed to improved outcomes of pregnancies in hemodialysis patients. However, conception rates are still limited and pregnancies are associated with a high risk of complications. Primary hyperoxalurias (PH) are a group of rare diseases caused by a genetic abnormality that results in excessive oxalate production. The most severe form, PH1, is caused by a mutation in alanine-glyoxylate aminotransferase gene which leads to progression to end-stage kidney disease by age of 60 years in 88% of patients [1, 2]. We present a case of a 25-year-old woman with chronic kidney disease secondary to PH1, diagnosed at the age of three when she presented with nephrolithiasis. The genetic analysis detected two mutations in the homozygous state in an AGTX gene: AGTX NM_000030.3:c.33dupC, p.(Lys12FInfs*156). Her parents were not blood relatives. She underwent multiple lithotripsies for the treatment of nephrolithiasis but was not in regular follow-ups due to noncompliance. In March 2020, she presented at the Emergency Department Unit in the terminal stage of kidney failure with the need for hemodialysis. The chronic hemodialysis protocol included four sessions weekly lasting for 4.5 h. Her menstrual cycles were irregular. On September 13, 2022, she reported amenorrhea. A gynecological workup revealed that she was approximately 24 weeks pregnant. She did not undergo genetic counseling before conception nor received any new medications. The hemodialysis program was intensified to five sessions per week, increasing dialysis time to 5 h. A Theranova 400 membrane (Baxter) was used and a dialysate bath was adjusted depending on laboratory results. Nadroparin was administered as an anticoagulant agent at a dose of 0.4 mL per session. She received paricalcitol, vitamin B6 3 50 mg, folic acid, pantoprazole 20 mg, and an oral nutritional supplement. Predialysis urea levels were maintained below 12.5 mmol/L. We also aimed to maintain normal calcium levels and hemoglobin concentration at approximately 110 g/L. Her dry weight was increased by 500 mg every 7 days corresponding to an increase in weight during normal pregnancies. The patient was hospitalized at 37 weeks of gestation and gave birth to a healthy 2450-g male baby 2 days later by Cesarean section. The postpartum course was uneventful. Her regular hemodialysis has been continued four times weekly. She is waiting for simultaneous liver–kidney transplantation and the approval of the use of lumasiran, with the skin ulcer on her leg indicating systemic oxalosis. Current treatment options for PH1 are limited. Simultaneous liver–kidney transplantation is used for patients with end-stage kidney failure [2]. Lumasiran is a novel liver-directed RNA interference therapeutic agent. It reduces hepatic oxalate production and increases concentrations of glycolate in patients with PH1, by degrading the messenger RNA that encodes glycolate oxidase, an enzyme upstream of alanineglyoxylate a","PeriodicalId":23021,"journal":{"name":"Therapeutic Apheresis and Dialysis","volume":"27 4","pages":"817-818"},"PeriodicalIF":1.9,"publicationDate":"2023-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9758457","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}